Should Sangamo's Failure Make CRISPR Investors Nervous?

The first look at a revolutionary new gene therapy from Sangamo Therapeutics (NASDAQ: SGMO) recently caused the stock to crash. Editas Medicine (NASDAQ: EDIT) and Crispr Therapeutics (NASDAQ: CRSP) are running their first studies with a different gene-editing technology, but their stock prices took a beating as well.